SLC5A2 and atherosclerosis: Compared with those without ASCVD, use of SGLT2 inhibitors (42.2% versus 35.7%; p<0.001) was significantly higher among patients with prior ASCVD, but not for GLP1-RAs (3.7% versus 5.9%) (Table 1 and Fig 3).